-
1
-
-
0035114558
-
Cancer statistics
-
Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics. CA Cancer J Clin 51(1): 15-36, 2001
-
(2001)
CA Cancer J Clin
, vol.51
, Issue.1
, pp. 15-36
-
-
Greenlee, R.T.1
Hill-Harmon, M.B.2
Murray, T.3
Thun, M.4
-
2
-
-
0001962044
-
Epithelial ovarian cancer
-
Hoskins WJ, Perez CA, Young RC (eds). Lippincott-Raven, Philadalphia, PA
-
Ozols RF, Rubin SC, Thomas G, Robboy S: Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC (eds) Principles and Practice of Gynecologic Oncology, 2nd edn. Lippincott-Raven, Philadalphia, PA, 1997, pp 919-986
-
(1997)
Principles and Practice of Gynecologic Oncology, 2nd Edn.
, pp. 919-986
-
-
Ozols, R.F.1
Rubin, S.C.2
Thomas, G.3
Robboy, S.4
-
3
-
-
0030054309
-
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
-
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334(1): 1-6, 1996
-
(1996)
N Engl J Med
, vol.334
, Issue.1
, pp. 1-6
-
-
McGuire, W.P.1
Hoskins, W.J.2
Brady, M.F.3
Kucera, P.R.4
Partridge, E.E.5
Look, K.Y.6
Clarke-Pearson, D.L.7
Davidson, M.8
-
4
-
-
0020408957
-
Isolation and structure of bryostatin-1
-
Pettit GR, Herald CL, Doubek DL, Herald D: Isolation and structure of bryostatin-1. J Am Chem Soc 104: 6846-6848, 1982
-
(1982)
J Am Chem Soc
, vol.104
, pp. 6846-6848
-
-
Pettit, G.R.1
Herald, C.L.2
Doubek, D.L.3
Herald, D.4
-
5
-
-
0033868507
-
Chemistry and clinical biology of the bryostatins
-
Mutter R, Wills M: Chemistry and clinical biology of the bryostatins. Bioorg Med Chem 8(8): 1841-1860, 2000
-
(2000)
Bioorg Med Chem
, vol.8
, Issue.8
, pp. 1841-1860
-
-
Mutter, R.1
Wills, M.2
-
6
-
-
0032721005
-
Pharmacology and clinical experience with bryostatin-1: A novel anticancer drug
-
Philip PA, Zonder JA: Pharmacology and clinical experience with bryostatin-1: a novel anticancer drug. Expert Opin Investig Drugs 8(12): 2189-2199, 1999
-
(1999)
Expert Opin Investig Drugs
, vol.8
, Issue.12
, pp. 2189-2199
-
-
Philip, P.A.1
Zonder, J.A.2
-
7
-
-
0027326957
-
A phase I study of intravenous bryostatin-1 in patients with advanced cancer
-
Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stem P, McDermott R, Potter M: A phase I study of intravenous bryostatin-1 in patients with advanced cancer. Br J Cancer 68(2): 418-424, 1993
-
(1993)
Br J Cancer
, vol.68
, Issue.2
, pp. 418-424
-
-
Prendiville, J.1
Crowther, D.2
Thatcher, N.3
Woll, P.J.4
Fox, B.W.5
McGown, A.6
Testa, N.7
Stem, P.8
McDermott, R.9
Potter, M.10
-
8
-
-
0003242881
-
A phase I and immunologic study of bryostatin-1 in patients with solid tumors
-
O'Reilly S, Slichenmyer W, Hess A, Donehower R: A phase I and immunologic study of bryostatin-1 in patients with solid tumors. Proc Amer Assoc Cancer Res 56: 802-808, 1996
-
(1996)
Proc Amer Assoc Cancer Res
, vol.56
, pp. 802-808
-
-
O'Reilly, S.1
Slichenmyer, W.2
Hess, A.3
Donehower, R.4
-
9
-
-
0034776809
-
Protein kinase c isozymes, novel phorbol ester receptors and cancer chemotherapy
-
Barry OP, Kazanietz MG: Protein kinase c isozymes, novel phorbol ester receptors and cancer chemotherapy. Curr Pharm Des 7(17): 1725-1744, 2001
-
(2001)
Curr Pharm Des
, vol.7
, Issue.17
, pp. 1725-1744
-
-
Barry, O.P.1
Kazanietz, M.G.2
-
10
-
-
0034280331
-
Protein kinase C as a drug target: Implications for drug or diet prevention and treatment of cancer
-
Carter CA: Protein kinase C as a drug target: implications for drug or diet prevention and treatment of cancer. Curr Drug Targets 1(2): 163-183, 2000
-
(2000)
Curr Drug Targets
, vol.1
, Issue.2
, pp. 163-183
-
-
Carter, C.A.1
-
11
-
-
0026628279
-
Sensitization of human cervical carcinoma cells to cisdiamminedichloroplatinum (II) by bryostatin-1
-
Basu A, Lazo JS: Sensitization of human cervical carcinoma cells to cisdiamminedichloroplatinum (II) by bryostatin-1. Cancer Res 52(11): 3119-3124, 1992
-
(1992)
Cancer Res
, vol.52
, Issue.11
, pp. 3119-3124
-
-
Basu, A.1
Lazo, J.S.2
-
12
-
-
0032876984
-
Bryostatin-1 enhances paclitaxel induced mitochondrial dysfunction and apoptosis in human leukemia cells (U927) ectopically expressing Bcl-xL
-
Wang S, Wang Z, Boise LH, Dent P, Grant S: Bryostatin-1 enhances paclitaxel induced mitochondrial dysfunction and apoptosis in human leukemia cells (U927) ectopically expressing Bcl-xL. Leukemia 13(10): 1564-1573, 1999
-
(1999)
Leukemia
, vol.13
, Issue.10
, pp. 1564-1573
-
-
Wang, S.1
Wang, Z.2
Boise, L.H.3
Dent, P.4
Grant, S.5
-
13
-
-
0034006706
-
The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow
-
Koutcher JA, Motwani M, Zakian KL, Li XK, Matei C, Dyke JP, Ballon D, Yoo HH, Schwartz GK: The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. Clin Cancer Res 6(4): 1498-1507, 2000
-
(2000)
Clin Cancer Res
, vol.6
, Issue.4
, pp. 1498-1507
-
-
Koutcher, J.A.1
Motwani, M.2
Zakian, K.L.3
Li, X.K.4
Matei, C.5
Dyke, J.P.6
Ballon, D.7
Yoo, H.H.8
Schwartz, G.K.9
-
14
-
-
0034486490
-
The addition of bryostatin-1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model
-
Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM: The addition of bryostatin-1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 6(12): 4950-4956, 2000
-
(2000)
Clin Cancer Res
, vol.6
, Issue.12
, pp. 4950-4956
-
-
Mohammad, R.M.1
Wall, N.R.2
Dutcher, J.A.3
Al-Katib, A.M.4
-
15
-
-
0035863313
-
Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412
-
Zaugg K, Rocha S, Resch H, Hegyi I, Oehler C, Glanzmann C, Fabbro D, Bodis S, Pruschy M: Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412. Cancer Res 61(2): 832-838, 2001
-
(2001)
Cancer Res
, vol.61
, Issue.2
, pp. 832-838
-
-
Zaugg, K.1
Rocha, S.2
Resch, H.3
Hegyi, I.4
Oehler, C.5
Glanzmann, C.6
Fabbro, D.7
Bodis, S.8
Pruschy, M.9
|